The Journal of Thoracic and Cardiovascular Surgery, Vol 81, 485-492, Copyright © 1981 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer
MF McKneally, C Maver, L Lininger, HW Kausel, JB McIlduff, TM Older, ED Foster and RD Alley
One hundred sixty-nine patients were entered into randomized controlled
studies of intrapleural bacille Calmette Guerin (BCG) immunotherapy after
surgical resection of lung cancer. Long-term follow-up of our initial
series of BCG-treated patients with Stage I disease continues to indicate
that this treatment was superior to that given to control patients. The
recurrence rate in the control population was high, 62% at 3 years. The
recurrence rate was 33% at 3 years in the BCG-treated group. A negative
preoperative tuberculin test and squamous cell histologic type were
favorable prognostic factors for BCG-treated patients. The survival of
patients with more advanced disease was not improved by BCG immunotherapy.